Antony Mattessich

In this Healio Video Perspective, Antony Mattessich, president and CEO of Ocular Therapeutix, discusses the continuing development of Dextenza (dexamethasone ophthalmic insert 0.4 mg).

SAN FRANCISCO — At the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology meeting, Antony Mattessich, CEO of Ocular Therapeutix, discusses Dextenza (dexamethasone ophthalmic insert 0.4 mg) as well as some of the company’s phase 1 programs.

SAN DIEGO ― At the Ophthalmology Innovation Summit, Antony Mattessich, president and CEO of Ocular Therapeutix, discusses the long-term vision for Dextenza, an intracanalicular insert of steroid for treatment of pain after ocular surgery.

NEW YORK — From OSN New York 2018, Antony Mattessich, CEO of Ocular Therapeutix, discusses progress toward approval of the dexamethasone implant, Dextenza, as well as other products in the company’s pipeline.

WAILEA, Hawaii — At Hawaiian Eye 2018, Antony Mattessich, president and CEO of Ocular Therapeutix, discusses the company’s plans moving forward into 2018.